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Abstract
Background: The human gut microbiota directly affects human health, and its alteration can lead to
gastrointestinal abnormalities and inflammation. Rett syndrome (RTT), a progressive neurological disorder mainly
caused by mutations in MeCP2 gene, is commonly associated with gastrointestinal dysfunctions and constipation,
suggesting a link between RTT’s gastrointestinal abnormalities and the gut microbiota. The aim of this study was to
evaluate the bacterial and fungal gut microbiota in a cohort of RTT subjects integrating clinical, metabolomics and
metagenomics data to understand if changes in the gut microbiota of RTT subjects could be associated with
gastrointestinal abnormalities and inflammatory status.
Results: Our findings revealed the occurrence of an intestinal sub-inflammatory status in RTT subjects as measured
by the elevated values of faecal calprotectin and erythrocyte sedimentation rate. We showed that, overall, RTT
subjects harbour bacterial and fungal microbiota altered in terms of relative abundances from those of healthy
controls, with a reduced microbial richness and dominated by microbial taxa belonging to Bifidobacterium, several
Clostridia (among which Anaerostipes, Clostridium XIVa, Clostridium XIVb) as well as Erysipelotrichaceae, Actinomyces,
Lactobacillus, Enterococcus, Eggerthella, Escherichia/Shigella and the fungal genus Candida.
We further observed that alterations of the gut microbiota do not depend on the constipation status of RTT
subjects and that this dysbiotic microbiota produced altered short chain fatty acids profiles.
Conclusions: We demonstrated for the first time that RTT is associated with a dysbiosis of both the bacterial and
fungal component of the gut microbiota, suggesting that impairments of MeCP2 functioning favour the
establishment of a microbial community adapted to the costive gastrointestinal niche of RTT subjects. The altered
production of short chain fatty acids associated with this microbiota might reinforce the constipation status of RTT
subjects and contribute to RTT gastrointestinal physiopathology.
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Background
Rett syndrome (RTT; OMIM #312750) is a severe and
progressive neurological disorder that almost exclusively
affects females with an incidence of ~1:10,000 live births
[1]. Loss-of-function mutations of the X-linked methyl-
CpG binding protein 2 (MeCP2) gene is the major cause
(approximately 90 %) of classical cases of RTT while
cyclin-dependent kinase-like 5 (CDKL5) and forkhead
box protein G1 (FOXG1) gene mutations represent the
remaining 10 % of the cases [2]. MeCP2 is a fundamen-
tal mediator of synaptic development and plasticity, and
its function is critical in the regulation of synaptic activ-
ities during early postnatal development [1]. Different
MeCP2 mutations are also known to correlate with the
clinical severity of RTT [3, 4] and the role of MeCP2 in
other neurodevelopmental disorders, such as autism, has
been demonstrated [5]. RTT subjects develop normally
up to 6–18 months of age after which they undergo a
period of neurological regression [1]. Microcephaly, dys-
praxia, stereotyped hand movements, transient autistic
features, respiratory abnormalities, bruxism, seizures and
gastrointestinal (GI) dysfunctions are symptoms com-
monly reported in RTT indicating it as a multisystemic
disorder [1]. Among the above-mentioned comorbidities,
several epidemiological studies indicated that GI dys-
functions are prevalent through the entire life of RTT
* Correspondence: c.de.filippo@ibimet.cnr.it
8Institute of Biometeorology (IBIMET), National Research Council (CNR), Via
Giovanni Caproni 8, I-50145 Florence, Italy
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Strati et al. Microbiome  (2016) 4:41 
DOI 10.1186/s40168-016-0185-y
subjects [6, 7] with constipation as one of the most fre-
quently reported GI symptoms [6, 7]. Recently, it has
been shown that the phenomenon of gut dismotility ob-
served in RTT may arise from impairments in the func-
tion of MeCP2 in the enteric nervous system (ENS) [8].
Nevertheless, the direct causes of these GI dysfunctions
are still unclear and the role of gut microbiota in host
physiology should not be neglected. Indeed, the human
gut microbiota plays a crucial role in the function and
integrity of the GI tract, maintenance of immune
homeostasis and host energy metabolism [9]. Alterations
in the composition of commensal bacterial population
can lead to chronic inflammation encompassing hyper-
activation of T-helper 1 and T-helper 17 immune re-
sponses [10], also predisposing individuals to fungal
infections [11]. Abnormal immunological response to
fungi can in turn contribute to systemic responses in-
cluding chronic inflammation as observed in inflamma-
tory bowel diseases [12]. Dysbioses of the gut microbiota
have been associated with an increasing number of
health conditions [13]. A strict relationship between the
gut microbiota and the central nervous system (CNS)
has been observed, and numerous studies have shown
alterations of the gut microbiota in the heterogeneous
group of neurological disorders belonging to the autism
spectrum disorders (ASDs) [14]. In addition, the gut
microbiota may modulate CNS activities through neural,
endocrine, metabolic and immune pathways [15] affect-
ing complex physiological and behavioural states of the
host [15, 16] so it is possible to hypothesize gut micro-
biota alterations in RTT as occur in ASDs. Supported by
the increasing appreciation of the gut-microbiome-brain
axis, we asked whether MeCP2 impairments in RTT
might affect also the composition of the gut microbiota
resulting in an eventual intestinal dysbiosis in RTT sub-
jects. Indeed, in the case of RTT, it is possible that alter-
ations in the composition of gut microbiota triggered by
the neurophysiological changes typical of the disease
could contribute to GI abnormalities and be an add-
itional factor relevant to previously observed cytokine
dysregulation and systemic inflammation [17, 18]. Here,
we characterized for the first time the intestinal micro-
biota, both bacterial and fungal, in subjects affected by
RTT in order to investigate the implication of gut micro-
organisms and their metabolism on RTT gastrointestinal
physiology evaluating also how the constipation status
may affect the composition of the gut microbiota in
RTT subjects.
Results
RTT is associated with mild intestinal inflammation
We analysed the inflammatory status and GI abnor-
malities in a cohort of 50 RTT subjects by measuring
the erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), serum IgA and faecal calprotectin
(Additional file 1: Table S1). We found that RTT sub-
jects presented elevated values of ESR (median value
22 mm/h; interquartile range 10–36.5 mm/h; average
26.8 ± 22.4 mm/h) and faecal calprotectin (median
value 63.45 μg/g; interquartile range 44–123 μg/g;
average 104 ± 97.8 μg/g) compared to a healthy popu-
lation [19, 20]. Constipation, one of the most common
GI symptoms of RTT, was present in 70.8 % of the ex-
amined RTT cohort, and it correlated with the titre of
serum IgA antibodies (Spearman’s r = 0.43, p = 0.011)
while the levels of serum IgA positively correlated
with the ESR values (Spearman’s r = 0.462, p = 0.011).
Constipation, ESR and serum IgA titre correlated with
the age of RTT subjects (Spearman’s r = 0.35, 0.409
and 0.596, respectively, p < 0.05) (Additional file 2:
Figure S1, Additional file 3: Table S2). Altogether,
these parameters confirmed the presence of a mild GI
inflammation in RTT subjects.
RTT subjects harbour an altered and less diverse gut
microbiota
We characterized the bacterial gut microbiota associated
with RTT by means of high-throughput sequencing of
the V3-V5 region of the 16S rDNA gene. We quantified
the bacterial richness within each sample (alpha-diver-
sity) of the two groups, RTT subjects and healthy con-
trols (hereinafter termed HC). Three different alpha-
diversity estimators were used, namely the observed
number of OTUs, the Chao1 index and the Shannon en-
tropy index. The bacterial gut microbiota of RTT sub-
jects was significantly less diverse compared to that of
HC (p < 0.005, Wilcoxon rank-sum test) with all the
three estimators used.
Since constipation affects more than the 70 % of the
RTT study cohort, we asked whether the constipation
status might be responsible for the differences observed
between RTT subjects and HC. The analysis of alpha-di-
versity revealed that, even when analysed separately,
both constipated and non-constipated RTT subjects (re-
spectively RTT-C and RTT-NC) harbour a less diverse
gut microbiota with respect to HC (p < 0.05, Wilcoxon
rank-sum test; Fig. 1a and Additional file 3: Figure S2a)
while there was no significant difference between RTT-C
and RTT-NC (p > 0.05, Wilcoxon rank-sum test; Fig. 1a
and Additional file 4: Figure S2a). To assess the robust-
ness of these results, we repeated the computation of
the alpha-diversity using 100 independent rarefactions
and for different values of the rarefaction depth. Alpha
rarefaction curves are reported in the Additional file 5:
Figure S3a.
To identify possible differences between the bacterial
components of the gut microbiota of RTT subjects and
HC, we calculated the beta-diversity of the samples using
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the unweighted and weighted UniFrac distances and the
Bray-Curtis dissimilarity. The Principal Coordinates Ana-
lysis (PCoA) based on these measures (Fig. 1b and Add-
itional file 4: Figure S2b) revealed that the gut microbiota of
RTT subjects was distinct from those of the HC (p ≤ 0.003,
PERMANOVA) (Table 1). The analysis of beta-diversity
among HC, RTT-C and RTT-NC revealed significant differ-
ences between HC and both RTT-C and RTT-NC (p ≤
0.003, PERMANOVA), but no significant difference was de-
tected when comparing the gut microbiota of RTT-C and
RTT-NC (Table 1). Multiple-rarefaction PCoA plots (“jack-
knifed” PCoA plots, [21]) (Additional file 6: Figure S4a and
Additional file 7: Figure S5a) were computed to assess the
robustness of bacterial beta-diversity analyses, showing that
these results hold independently from rarefaction.
Bifidobacterium is the hallmark of intestinal dysbiosis in
RTT
Since we did not observe population differences in the gut
microbiota of RTT subjects in function of the constipation
status, only the health condition of the subjects (i.e., healthy
or RTT) was considered in the following analyses. To iden-
tify the taxa that were differentially represented in HC and
RTT subjects, we compared the relative abundances be-
tween these two groups at different taxonomic levels.
Phylum level analysis showed that Actinobacteria was
the most abundant phylum in RTT with a significant in-
crease of its relative abundance in RTT subjects compared
to HC (p = 0.0017, Wilcoxon rank-sum test; Additional file
8: Table S3 and Additional file 9: Table S4). Furthermore,
while Firmicutes was the most abundant phylum in HC,
we observed a significant decrease of the relative abun-
dance of Bacteroidetes in RTT subjects (p = 0.002,
Wilcoxon rank-sum test; Additional file 8: Table S3 and
Additional file 9: Table S4). Indeed, the significant increase
of the Firmicutes/Bacteroidetes ratio, a rough estimator of
intestinal dysbiosis, in RTT subjects (median value 3.95)
compared to HC (median value 1.64) (p = 0.003, Wilcoxon
rank-sum test) indicated the presence of an intestinal dys-
biosis associated with RTT.
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Fig. 1 Measures of bacterial diversity. a Alpha-diversity calculated on the number of observed OTUs; ***p < 0.0001; **p < 0.001; ns, not significant;
Wilcoxon rank-sum test. b, c PCoA plots of bacterial beta-diversity based on b the Weighted UniFrac distance and c the Bray-Curtis dissimilarity
analysed according to individuals’ health status. Constipated Rett syndrome subjects (RTT-C), non-constipated Rett syndrome subjects (RTT-NC)
and healthy controls (HC) are coloured in red, orange or green, respectively
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Analysis of the relative abundance of bacterial taxo-
nomic groups at the genus level showed that the ten
most abundant genera were Bifidobacterium (mean
relative abundance, RTT, 36.7 %; HC, 17.2 %), Bacter-
oides (RTT, 12.3 %; HC, 18.3 %), Faecalibacterium
(RTT, 3.6 %; HC, 9.2 %), Lachnospiracea incertae sedis
(RTT, 4.6 %; HC, 3.9 %), Blautia (RTT, 4.7 %; HC,
3.7 %), Escherichia/Shigella (RTT, 5.2 %; HC, 2.4 %),
Alistipes (RTT, 1.3 %; HC, 4.7 %), Streptococcus (RTT,
2.3 %; HC, 2.9 %), Gemmiger (RTT, 1.1 %; HC, 3.1 %)
and Ruminococcus (RTT, 1.5 %; HC, 2.2 %) (Additional
file 10: Figure S6 and Additional file 8: Table S3). Com-
paring the relative abundance of all the genera among
the two groups of study, we discovered Actinomyces,
Bifidobacterium, Clostridium XIVa Eggerthella, Entero-
coccus, Erysipelotrichaceae incertae sedis, Escherichia/
Shigella and Megasphaera, as significantly more abun-
dant in RTT subjects compared to HC while several
other bacterial genera usually associated with a
healthy human gut were less abundant in RTT sub-
jects compared to HC (p < 0.05, Wilcoxon rank-sum
test; Additional file 11: Figure S7, Additional file 8:
Table S3 and Additional file 9: Table S4).
To define more precisely the taxa that were driving
the differentiation of the microbiota of the groups, we
performed an analysis based on PhyloRelief [22], a re-
cent phylogenetic-based feature weighting algorithm
for metagenomics data. Being independent from a pre-
compiled taxonomy, PhyloRelief includes in the analysis
unclassified taxa that would be otherwise ignored by
other methods. The PhyloRelief analysis confirmed that
the Bifidobacterium clade was significantly more repre-
sented in RTT subjects with respect to HC (Fig. 2). In
addition, several OTUs classified as belonging to differ-
ent members of Clostridia (e.g., Anaerostipes, Clostrid-
ium XIVb, unknown-Lachnospiraceae) as well as
Erysipelotrichaceae (Clostridium XVIII and Erysipelotri-
chaceae incertae sedis), Actinomyces, Lactobacillus,
Eggerthella, Enterococcus and Enterobacteriaceae (in
particular Escherichia/Shigella) were significantly more
abundant in the gut microbiota of RTT subjects com-
pared to HC (Fig. 2). Remarkably, the PhyloRelief ana-
lysis identified significant differences in the taxa
Anaerostipes, Clostridium XIVb, Clostridium XVIII,
Lactobacillus and Clostridium IV that went undetected
by using the Wilcoxon rank-sum test (Additional file 9:
Table S4).
Differentially abundant taxa were further confirmed by
LEfSe [23], an algorithm for high-dimensional biomarker
discovery which exploits linear discriminant analysis
(LDA) to robustly identify features statistically different
among classes. Figure 3 shows the most relevant clades
identified by LEfSe (logarithmic LDA score > 2.0; see also
Additional file 12: Figure S8).
To evaluate the absolute amount of Bifidobacterium
and validate their increase in RTT-associated dysbiosis,
we performed quantitative PCR analysis (qPCR). We ob-
served that Bifidobacterium was twofold more abundant
in RTT subjects than in HC (median values
4.08*108 CFU/g and 1.99*108 CFU/g, respectively; p =
0.009, Wilcoxon rank-sum test; Fig. 4a). We also noticed
that among the Bifidobacterium species investigated,
Bifidobacterium longum ssp. longum was significantly
more abundant in RTT subjects compared to HC (me-
dian values 4.94*108 CFU/g and 2.44*108 CFU/g respect-
ively; p = 0.019, Wilcoxon rank-sum test; Fig. 4b).
High levels of faecal short chain fatty acids in RTT
subjects
PICRUSt was used for inference of microbial metabolic
pathways [24] in the gut microbiota of RTT subjects and
HC (Additional file 13: Table S5). The analysis predicted
the enrichment, among others, of carbohydrate and pro-
panoate metabolism in the gut microbiota of RTT sub-
jects, which are metabolic pathways related also to the
metabolism of short chain fatty Acids (SCFAs). Since
SCFAs are important for colonic health and may act on
neuronal physiology [9, 25, 26], we measured the faecal
content of SCFAs in our samples by means of GC-MS.
Table 1 Permutational multivariate analysis of variance
(PERMANOVA) tests of the bacterial gut microbiota on the
unweighted and weighted UniFrac distances and the Bray-
Curtis dissimilarity according to individuals’ health status and
constipation
Metric F R2 p value*
HC (n = 29)
vs
RTT (n = 50)
Unweighted UniFrac 6.84 0.08 ≤0.003
Weighted UniFrac 15.6 0.16 ≤0.003
Bray-Curtis 6.94 0.08 ≤0.003
HC (n = 29)
vs
RTT-C (n = 34)
Unweighted UniFrac 5.59 0.08 ≤0.003
Weighted UniFrac 12.1 0.16 ≤0.003
Bray-Curtis 5.39 0.08 ≤0.003
HC (n = 29)
vs
RTT-NC (n = 14)
Unweighted UniFrac 5.27 0.11 ≤0.003
Weighted UniFrac 8.75 0.17 ≤0.003
Bray-Curtis 5.47 0.11 ≤0.003
RTT-C (n = 34)
vs
RTT-NC (n = 14)
Unweighted UniFrac 1.31 0.02 0.180
Weighted UniFrac 1.10 0.02 0.687
Bray-Curtis 1.76 0.03 0.180
HC healthy controls, RTT-C constipated Rett syndrome subjects, RTT-NC non-
constipated Rett syndrome subjects
*Bonferroni corrected p values
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Fig. 2 (See legend on next page.)
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We observed that the overall content of SCFAs in
RTT subjects’ faeces was higher than in HC (median
values RTT, 191.5 μmol/g; HC 156.6 μmol/g). Particu-
larly, we observed that propionate (median values
RTT, 20.4 μmol/g; HC 13.2 μmol/g), isovalerate\2-
methylbutyrate (median values RTT, 4.7 μmol/g; HC
2.2 μmol/g) and isobutyrate (median values RTT,
3.1 μmol/g; HC 1.6 μmol/g) were significantly more
abundant in RTT subjects than HC (p < 0.05,
Wilcoxon rank-sum test; Fig. 5).
RTT-associated gut mycobiota shows clear population
composition differences compared to HC
The human gut mycobiota has been poorly explored so
far, although there is an increasing awareness of its im-
portance in human (patho)physiology [27]. We charac-
terized the gut mycobiota of the study cohort by means
of high-throughput sequencing of the ITS1 region of the
ribosomal Internal Transcribed Spacer (ITS).
High-quality fungal sequences were detected respect-
ively in 49 out of 50 RTT subjects and 28 out of 29 HC.
The analysis of the alpha-diversity revealed that the gut
mycobiota of RTT subjects, both constipated and non-
constipated, was slightly less diverse compared to HC
even if no significant differences were observed (p > 0.05,
Wilcoxon rank-sum test; Additional file 14: Figure S9a).
Alpha rarefaction curves (using 100 independent rare-
factions) are reported in the Additional file 5: Figure
S3b. As for the bacterial microbiota, a PERMANOVA
analysis on the unweighted, weighted UniFrac distances
and Bray-Curtis dissimilarity revealed that the gut myco-
biota of RTT subjects was significantly different from
that of HC (p < 0.05, PERMANOVA; Table 2, Fig. 6 and
Additional file 14: Figure S9b), while no significant dif-
ference was detected between the gut mycobiota of con-
stipated and non-constipated RTT subjects (Table 2).
Multiple-rarefaction PCoA plots (“jackknifed” PCoA
plots, [21]) (Additional file 6: Figure S4b and Additional
file 7: Figure S5b) computed to assess the robustness of
the fungal beta-diversity analyses showed that the un-
weighted UniFrac measure on the gut mycobiota was
sensitive to rarefaction (although PERMANOVA p
values were significant, see Additional file 7: Figure S5b),
while the other beta-diversity measures support a differ-
entiation between the gut mycobiota of HC and RTT
subjects.
The genus Candida predominates in the altered gut
mycobiota of RTT subjects
Metataxonomics analysis of the gut mycobiota led to the
identification of 77 fungal taxa unambiguously classified
to the genus level and 19 taxa only partially classified.
The ten most abundant annotated fungal genera were
Candida (RTT 61.3 %; HC 25.5 %), Penicillium (RTT
13.5 %; HC 19.4 %), Aspergillus (RTT 7.3 %; HC 6.5 %),
Malassezia (RTT 3.5 %; HC 4.5 %), Debaryomyces (RTT
1.7 %; HC 5.5 %), Mucor (RTT 1.1 %; HC 4.6 %), Ere-
mothecium (RTT 0.07 %; HC 3.7 %), Pichia (RTT 0.1 %;
HC 3.5 %), Cyberlindnera (RTT 0.5 %; HC 1.7 %), and
Trichosporon (RTT 1.3 %; HC 0.007 %) (Additional file
15: Figure S10). The relative abundance of the genus
Candida was significantly higher in RTT subjects than
HC (p = 0.002, Wilcoxon rank-sum test; Additional file
16: Figure S11). Remarkably, we detected sequences be-
longing to the single-cell protozoa Blastocystis in differ-
ent healthy controls (in 24.1 % of the inspected healthy
individuals) while this genus was present only in one
RTT subject. Blastocystis is an important eukaryote of
the GI tract of healthy individuals [28] being less com-
mon in subjects affected by irritable bowel syndrome
and inflammatory bowel diseases [29]. The reported high
relative abundance of the genus Candida in the gut
mycobiota of RTT subjects was further confirmed by
LEfSe analysis (Additional file 17: Figure S12).
Discussion
Our study identified a clear dysbiosis of the fungal and
bacterial gut microbiota in individuals affected by RTT, a
neurological disorder also associated with gastrointestinal
symptoms and systemic inflammation. The elevated values
of calprotectin and ESR measured in RTT subjects correl-
ating also with the titre of serum IgA antibodies indicated
the occurrence of an intestinal sub-inflammatory status,
in line with previous indication of a pro-inflammatory sta-
tus in MeCP2-related RTT [18]. A state of intestinal in-
flammation is also related to loss of intestinal barrier
function and the subsequent translocation of pathobionts
that may induce systemic responses [10]. RTT subjects
displayed on average a lower bacterial gut microbiota rich-
ness and diversity compared to HC. We observed a sig-
nificant increase in the Firmicutes/Bacteroidetes ratio in
RTT subjects due to a reduction of the relative abundance
of Bacteroidetes in these subjects. An increased Firmi-
cutes/Bacteroidetes ratio has recently been reported also
(See figure on previous page.)
Fig. 2 PhyloRelief analysis (RTT vs HC) of bacterial OTUs using the unweighted UniFrac distance. The heat-map shows the relative abundances of
the OTUs that are differentially represented in Rett syndrome (RTT) subjects and healthy controls (HC) (PhyloRelief selected clades with FDR-
corrected p < 0.01, Kruskal-Wallis test). OTUs are classified according to their genus on the left side of the figure. The OTUs more represented in
RTT subjects than HC are highlighted in bold characters. The ultrametric pruned phylogenetic tree of the OTUs is shown on the right side of the
figure. RTT subjects and healthy controls are coloured in red and green, respectively. Abundances are expressed in terms of their z-score
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Fig. 3 Cladogram showing the most discriminative bacterial clades identified by LEfSe. Coloured regions/branches indicate differences in the
bacterial population structure between Rett syndrome (RTT) subjects and healthy controls (HC). Regions in red indicate clades that were enriched
in RTT subjects compared to those in HC, while regions in green indicate clades that were enriched in HC compared to those in RTT subjects
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in children affected by autism [30], and treatment with
Bacteroides fragilis has been shown to restore autism-
related behavioural and GI abnormalities in a mouse
model of neurodevelopmental disorders [31].
An in-depth analysis of bacterial taxa revealed that the
relative abundances of Bifidobacterium and several Clos-
tridia, i.e. Anaerostipes, Clostridium XIVa, and Clostrid-
ium XIVb, as well as Erysipelotrichaceae (Clostridium
XVIII and Erysipelotrichaceae incertae sedis), Actinomyces,
Eggerthella, Enterococcus, Escherichia/Shigella and Lacto-
bacillus, were significantly higher in RTT subjects than in
HC. Bifidobacteria are well recognized as health-
promoting bacteria [32], with potential probiotic proper-
ties [33], and have been rarely associated with pathological
states [34, 35]. Measuring the absolute abundances of the
most common intestinal Bifidobacterium species by
qPCR, we found that Bifidobacterium longum ssp. longum
was the most abundant in RTT subjects, with absolute
abundance twofold higher than in HC. The reported high
abundance of Bifidobacterium in RTT subjects could indi-
cate Bifidobacterium adaptation to the GI niche associated
with RTT.
In line with our results, various studies on the gut
microbiota of ASDs subjects reported also the increased
incidence of Clostridia [36, 37], one of the most abun-
dant Gram-positive bacteria known to reside in the hu-
man gut. Moreover, Erysipelotrichaceae, Lactobacillus
and Escherichia/Shigella resulted to be enriched in ASDs
[38, 39] in concomitance with a reduction of Prevotella
[39], consistently with our observations. Prevotella is an
important member of the human gut microbiota in-
volved in the maintenance of the microbial community
structure [40] while Escherichia/Shigella genera may
exert pro-inflammatory activities and are abundant in
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Fig. 5 SCFAs faecal content. Bar-plot representation of the median values of faecal SCFAs in Rett syndrome (RTT) subjects and healthy controls
(HC); *p < 0.05, **p < 0.005, ***p < 0.0005, Wilcoxon rank-sum test
Strati et al. Microbiome  (2016) 4:41 Page 8 of 15
subjects with active states of intestinal inflammation [41,
42]. However, given the lack of a consensus [14] and the
methodological differences, it is difficult to draw general
conclusions by directly comparing the results of the dif-
ferent studies on ASDs’ gut microbiota.
It is well known that perturbations in the composition of
commensal bacteria can predispose individuals to fungal in-
fections [43]. We observed a dysbiotic gut mycobiota
associated with RTTcharacterized by an altered community
structure dominated by the genus Candida. Candida is
one of the most common fungal commensals of the GI
tract [28] but bacterial dysbiosis can shift Candida com-
mensalism to pathogenesis, leading to extended infections
and candidiasis [44]. It was also observed that the propor-
tion of opportunistic pathogenic fungi, including Candida,
increases in a mouse model of intestinal inflammation [12].
The herein described intestinal dysbiosis could be asso-
ciated with changes in gut metabolite profiles conse-
quently affecting the RTT gastrointestinal physiology.
Bifidobacterium as well as Anaerostipes, Clostridium
XIVa, Clostridium XIVb and Clostridium XVIII are known
producer of SCFAs as fermentation end-products of car-
bohydrates and proteins [45]. Also, the lactic-acid bacteria
Lactobacillus and Enterococcus can sustain the production
of SCFAs through cross-feeding mechanisms that involves
lactate-utilizing gut bacteria [46]. We observed that the
faecal content of SCFAs in RTT subjects was significantly
enriched in propionate, isobutyrate and isovalerate\2-
methylbutyrate. Non-physiological high levels of SCFAs in
the gut could contribute to GI symptoms, including the
constipation status (which affect more of the 70 % of this
RTT study cohort), through the alteration of goblet cell
mucin discharge [47] and the inhibition of smooth muscle
contraction in the colon [48] mediated by the release of
the peptide YY from enteroendocrine cells [49]. Also, pro-
longed exposure to protein-derived SCFAs (among which
isobutyrate, 2-methylbutyrate and isovalerate) and other
protein fermentation products, such as ammonia, phen-
olic compounds or p-cresol, may affect the metabolism
and the physiology of colonocytes [50]. Remarkably, en-
teric SCFAs, principally propionate and butyrate, can
modulate gene expression, brain function and behaviour,
affecting neurotransmitter systems, neuronal cell adhe-
sion, inflammation, oxidative stress, lipid metabolism and
Table 2 Permutational multivariate analysis of variance
(PERMANOVA) tests of the gut mycobiota on the unweighted
and weighted UniFrac distances and the Bray-Curtis dissimilarity
according to individuals’ health status and constipation
Metric F R2 p value*
HC (n = 28)
vs
RTT (n = 49)
Unweighted UniFrac 2.76 0.03 0.006
Weighted UniFrac 7.45 0.09 ≤0.003
Bray-Curtis 6.84 0.08 0.006
HC (n = 28)
vs
RTT-C (n = 33)
Unweighted UniFrac 2.23 0.03 0.018
Weighted UniFrac 5.60 0.08 0.009
Bray-Curtis 5.82 0.08 ≤0.003
HC (n = 28)
vs
RTT-NC (n = 14)
Unweighted UniFrac 2.00 0.04 0.036
Weighted UniFrac 5.95 0.12 ≤0.003
Bray-Curtis 4.59 0.10 0.006
RTT-C (n = 33)
vs
RTT-NC (n = 14)
Unweighted UniFrac 1.01 0.02 1.000
Weighted UniFrac 1.27 0.02 0.837
Bray-Curtis 1.00 0.02 1.000
HC healthy controls, RTT-C constipated Rett syndrome subjects, RTT-NC non-
constipated Rett syndrome subjects
*Bonferroni corrected p values
HC
RTT-C
RTT-NC
Bray-Curtis, PCoA
P
C
2 
[1
2.
3%
]
PC1 [33%]
bWeighted UniFrac, PCoA
P
C
2 
[1
9.
2%
]
PC1 [41.2%]
a
Fig. 6 Measures of fungal beta-diversity. PCoA plots of fungal beta-diversity based on a the Weighted UniFrac distance and b the Bray-Curtis dissimilarity
analysed according to individuals’ health status. Constipated Rett syndrome subjects (RTT-C), non-constipated Rett syndrome subjects (RTT-NC) and healthy
controls (HC) are coloured in red, orange or green, respectively
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mitochondrial function in rat and in vitro cell models of
ASDs [51, 52].
Taken together, these observations suggest that func-
tional impairments of MeCP2 favour the establishment
of both constipation and adaptation of an intestinal dys-
biotic microbial community that may reinforce the con-
stipation status through non-physiological levels of
SCFAs. Nevertheless, we are not able to infer the conse-
quentiality of the two phenomenons, i.e. constipation or
dysbiosis. The SCFAs produced by the gut microbiota
are thus potentially implicated in the chronic constipa-
tion often associated with RTT, yet their role in the
pathophysiology of RTT remains elusive. Indeed, the
high faecal content of SCFAs in RTT subjects could be
also related to a reduced intestinal absorption of these
and other metabolites in the gut [53], or to increased lib-
eration of SCFAs due to fibre retention in a costive gut.
The establishment of intestinal dysbiosis, both at bacter-
ial and fungal level, may reinforce, rather than deter-
mine, constipation, which is one of the most common
GI problems in RTT. It is worth noting that the consti-
pation status correlates with age suggesting that consti-
pation and intestinal dysbiosis could be temporally
connected with the progression of the disease. Further-
more, the reduction of the mucin layer due to the inhib-
ition of goblet cells induced by the high levels of SCFAs
might trigger an immunological response that might
boost ERS values, serum IgA and the levels of calprotec-
tin simplifying the putative translocation through the in-
testinal barrier of pathobionts equipped with proper
virulence factors, such as Candida and Escherichia/Shi-
gella, and overall contributing to systemic inflammation
and cytokine dysregulation.
Conclusions
Here, we demonstrated for the first time that RTT is
characterized by a dysbiotic bacterial and fungal
microbiota showing an overall reduction of the mi-
crobial richness and diversity as well as an altered
composition of the microbial community structure in
RTT subjects. In particular, the increase in the rela-
tive abundance of Bifidobacterium, Clostridia and
Candida drives the dysbiotic state associated with
RTT. We hypothesize that impairments of MeCP2
functioning promote the establishment of a dysbiotic
intestinal microbial community that, in turn, could
affect RTT gastrointestinal physiopathology through
altered SCFAs production, reinforcing the constipa-
tion status itself and favouring inflammation and
cytokine dysregulation. Due to the importance that
our findings might have in the design of potential
therapeutic interventions aimed at gastrointestinal
relief in RTT, we are planning to further investigate
the gut microbiota dynamics during the progression
of the disease in a MeCP2-null mouse model apply-
ing specific probiotics and prebiotics treatments.
Methods
Study participants and sample handling and collection
We recruited 50 female subjects with clinical diagnosis
of RTT (average age 12 ± 7.3), genotyped for MeCP2
and CDKL5 gene mutations (Additional file 1: Table
S1) and 29 age-matched healthy subjects as controls
(average age 17 ± 9.6) (Additional file 18: Table S6).
RTT subjects with clinically evident inflammatory con-
ditions (i.e. upper respiratory tract infection, pneumo-
nia, urinary infection, stomatitis and periodontal
inflammation), either acute or chronic, were excluded.
A “compressed” clinical severity score (CSS) was attrib-
uted to RTT subjects following thirteen criteria: regres-
sion, microcephaly, somatic growth, independent
sitting, ambulation, hand use, scoliosis, language, non-
verbal communication, respiratory dysfunction, auto-
nomic symptoms, stereotypies and seizures [4]. ESR,
CRP and serum IgA levels were assessed as markers of
inflammation or GI abnormalities. Gastrointestinal
symptoms (i.e. constipation) and intestinal inflamma-
tion (i.e. faecal calprotectin levels) [54] were also
assessed (Additional file 1: Table S1). The diagnosis of
constipation was defined according to Rome III criteria
[55]. Stool samples from enrolled subjects were col-
lected, aliquoted as it is and stored at −80 °C until
analysis. All subjects of this study were under a
Mediterranean-based diet and no antibiotics, probiotics
or prebiotics have been taken in the 3 months prior the
sample collection. The study was approved by the insti-
tutional review board of the Siena University Hospital
(AOUS, Siena, Italy), and all enrolled subjects or tutors
gave written informed consent in accordance with the
sampling protocol approved by the local Ethical Com-
mittee (No. 2012-005021-76).
Faecal calprotectin assay
Calprotectin determination was performed by using a
polyclonal antibody in an enzyme-linked immunosorb-
ent assay (Calprest, Eurospital, Trieste, Italy).
Briefly, frozen stool samples were thawed at room
temperature; 100 mg of faeces (wet weight) were weighed
and placed in a disposable screw cap-tube containing the
extraction buffer (weight/volume 1:50). Samples were then
mixed vigorously for 30 s, homogenized for 25 min on a
shaker, and centrifuged for 20 min at 10,000g at room
temperature; 0.5 ml of clear extract supernatant was trans-
ferred to new tubes and stored at –80 °C. Finally, samples
were diluted 1:50, and absorbance was measured at
405 nm. According to the manufacturer’s instructions,
normal values were considered <50 μg/g of calprotectin
per faecal sample.
Strati et al. Microbiome  (2016) 4:41 Page 10 of 15
DNA extraction, PCR amplification of the V3-V5 region of
bacterial 16S rDNA and of the ITS1 region of fungal rDNA
Total DNA extraction from faecal samples (250 mg, wet
weight) was performed using the FastDNA™ SPIN Kit for
Feces (MP Biomedicals, Santa Ana, CA, USA) following
manufacturer’s instructions. DNA integrity and quality
were checked on 1 % agarose gel TAE 1X and quantified
with a NanoDrop® spectrophotometer. For each DNA sam-
ple, 16S rRNA gene was amplified using fusion primer set
specific for V3-V5 hypervariable regions (357F: 5′-
TCCTACGGGAGGCAGCAG-3′ and 937R: 5′-TGTGCG
GGCCCCCGTCAATT-3′) containing adaptors, key
sequence and barcode (Multiple IDentifier) sequences as
described by the 454 Sequencing System Guidelines for
Amplicon Experimental Design (Roche, Basel, Switzerland).
PCR reactions were performed using the FastStart
High Fidelity PCR system (Roche, Basel, Switzerland) ac-
cording to the following protocol: 5 min at 95 °C, 25 cy-
cles of 30 s at 95 °C, 30 s at 58 °C and 1 min at 72 °C,
followed by a final extension of 8 min at 72 °C. The PCR
reaction mix contained 1X FastStart High Fidelity PCR
buffer 1.8 mM MgCl2, 200 μM of dNTPs, 0.4 μM of
each primer (Eurofins, PRIMM, Milano, Italy), 2.5 U of
FastStart High Fidelity Polymerase Blend and 10 ng of
gDNA as template. For ITS1 amplicon sequencing, fu-
sion primer sets were designed as described above
coupled with forward primer 18SF (5′-GTAAAAGTCG-
TAACAAGGTTTC-3′) and reverse primer 5.8S1R (5′-
GTTCAAAGAYTCGATGATTCAC-3′) [56] specific for
fungal ITS1 rDNA region. The PCR reaction mix con-
tained 1X FastStart High Fidelity PCR buffer, 2 mM
MgCl2, 200 μM of dNTPs, 0.4 μM of each primer
(PRIMM, Milano, Italy), 2.5 U of FastStart High Fidelity
Polymerase Blend and 100 ng of gDNA as template.
Thermal cycling conditions used were 5 min at 95 °C,
35 cycles of 45 s at 95 °C, 45 s at 56 °C and 1.30 min at
72 °C followed by a final extension of 10 min at 72 °C.
All PCR experiments were carried out in triplicates
using a Veriti® Thermal Cycler (Applied Biosystems, Fos-
ter City, CA, USA).
Library construction and pyrosequencing
The PCR products obtained were analysed by gel
electrophoresis and cleaned using the AMPure XP
beads kit (Beckman Coulter, Brea, CA, USA) follow-
ing the manufacturer’s instructions, quantified via
quantitative PCR using the Library quantification
kit—Roche 454 titanium (KAPA Biosystems, Boston,
MA) and pooled in equimolar way in a final amplicon
library. The 454 pyrosequencing was carried out on
the GS FLX+ system using the XL+ chemistry follow-
ing the manufacturer’s recommendations (Roche, Ba-
sel, Switzerland).
qPCR analysis
Amplifications of Bifidobacterium sp. 16S rDNA gene were
performed in triplicate for each sample using the KAPA
SYBR® FAST qPCR Kit Optimized for LightCycler® 480
(Kapa Biosystems, Inc., Wilmington, MA, USA) and the
LightCycler® 480 II instrument (Roche, Basel, Switzerland)
with primers and protocols described previously [57, 58].
The PCR reaction mix contained 1X KAPA SYBR FAST
qPCR Master Mix, 0.2 μM of each Bifidobacterium-specific
primer and 10 ng of gDNA as template. For quantification
of each Bifidobacterium species, we constructed a seven-
point standard curve consisting in tenfold serial dilutions of
gDNA extracted from a pure culture at known concentra-
tion. For quantification of the genus Bifidobacterium, we
used the strain Bifidobacterium animalis ssp. lactis BB12.
The following Bifidobacterium type strains were used
for the species-specific quantification: B. angulatum
ATCC27535, B. adolescentis ATCC15703, B. animalis
ssp. lactis ATCC15705, B. bifidum DSM20456, B.
breve ATCC15700, B. dentium ATCC27534, B. longum
ssp. infantis ATCC15697, B. longum ssp. longum
ATCC15707 and B. pseudocatenulatum ATCC27917.
Amplification specificity of target gene was checked
by melting curve analysis. Efficiency and reliability of
PCR amplifications were calculated.
SCFAs analysis
Frozen faecal samples (∼150 mg, wet weight) were di-
luted 1:10 in sterile PBS 1 M (pH 7.2) and centri-
fuged at 13.000g for 5 min. Supernatants were then
filtered using a 0.2-μm polycarbonate syringe filter
and acidified by the addition of one volume of HCl
6 M to three volumes of sample. After 10-min incu-
bation at room temperature, samples were centrifuged
at 13.000g for 5 min. One volume of 10 mM 2-
ethylbutyric acid was added to four volumes of sam-
ple as internal standard. Calibration was done using
standard solutions of acetate, propionate, butyrate,
isobutyrate, 2-methyl-butyrate (2-MeBut), valerate and
isovalerate in acidified water (pH 2). Standard solu-
tions containing 50, 20, 10, 5, 1 and 0.5 mM of each
external standard were used.
Analysis was performed using a TRACE™ Ultra Gas
Chromatograph (Thermo Scientific, Waltham, MA, USA)
coupled to a TSQ Quantum GC mass spectrometric de-
tector (Thermo Scientific, Waltham, MA, USA). SCFAs
were separated using a Restek Stabilwax-DA (30 m×
0.25 mm; 0.25-μm film thickness) (Restek corp., Bellafonte,
PA, USA). The injected sample volume was 1 μl in split
mode with a ratio of 10:1. The initial oven temperature was
at 90 °C and maintained for 0.5 min and then increased
20 °C/min to 240 °C. The carrier gas helium was delivered
at a flow rate of 1 ml min−1. The temperatures of the inlet,
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transfer line and electron impact (EI) ion source were set at
280, 250 and 250 °C, respectively. The electron energy was
70 eV, and the mass spectral data was collected in a full
scan mode (m/z 30–200).
Data analysis
Pyrosequencing resulted in a total of 2,227,864 reads
for 16S rDNA with a mean of 27,987 ± 5782 sequences
per sample and 1,678,227 reads for ITS1 region with a
mean of 21,118 ± 13,270 sequences per sample. Raw
454 files were demultiplexed using the Roche’s sff file
software and submitted to the European Nucleotide
Archive with accession number PRJEB12607. Sample
accession IDs and metadata are available in Additional
file 18: Table S6. Reads were pre-processed using the
MICCA pipeline (http://www.micca.org) [59]. Forward
and reverse primer trimming and quality filtering were
performed using micca-preproc. De novo sequence
clustering, chimera filtering and taxonomy assignment
were performed by micca-otu-denovo: operational
taxonomic units (OTUs) were assigned by clustering
the sequences with a threshold of 97 % pairwise iden-
tity, and their representative sequences were classified
using the RDP classifier version 2.7 on 16S rDNA data
and using the RDP classifier version 2.8 [60] against the
UNITE fungal ITS database [61] on ITS1 data.
Template-guided multiple sequence alignment (MSA)
was performed using PyNAST [62] (v. 0.1) against the
multiple alignment of the Greengenes [63] database (re-
lease 13_05) filtered at 97 % similarity for bacterial se-
quences and through de novo MSA using T-Coffee [64]
for fungal sequences. Fungal taxonomy assignments
were also manually curated using BLASTn against the
GenBank’s database for accuracy. High-quality fungal
sequences have been also manually filtered out for se-
quences belonging to Agaricomycetes (unlikely to be
residents of the human gut due to their ecology) [65].
Samples with less than 1000 reads have been excluded
from the analysis. The phylogenetic trees were inferred
using micca-phylogeny [66]. Sampling heterogeneity
was reduced rarefying samples at 90 % of the less abun-
dant sample (16S data) and at the depth of the less
abundant sample (ITS1 data). Alpha- (within-sample
richness) and beta-diversity (between-sample dissimi-
larity) estimates were computed using the phyloseq R
package [67]. Multiple-rarefaction PCoA plots (“jack-
knifed” PCoA plots, [21]) were computed to assess the
robustness of the beta-diversity analyses. Permutational
MANOVA (PERMANOVA) was performed on the Uni-
Frac distances and Bray-Curtis dissimilarity using the
adonis() function of the vegan R package with 999 per-
mutations, and p values were corrected using the
Bonferroni correction [68]. The non-parametric Wil-
coxon rank-sum test was used for the comparison of
relative abundances of microbial taxa between groups,
and the resulting p values were corrected for multiple
testing controlling the false discovery rate [69] at all
taxonomic levels taken into account. Further identifica-
tion of taxa differentially distributed in case/control
groups was obtained by PhyloRelief, a phylogenetic-
based feature weighting algorithm for metagenomics
data. This method unambiguously groups taxa into
clades without relying on a precompiled taxonomy and
accomplishes a ranking of the clades according to their
contribution to the sample differentiation [22]. Linear
discriminant effect size analysis (LEfSe) [23] with de-
fault parameters was performed to find taxonomic
clades differentially represented between RTT subjects
and HC. LEfSe combines Kruskal-Wallis test and Wil-
coxon rank-sum tests with linear discriminant analysis
(LDA). LEfSe ranks features by effect size, putting at
the top features that explain most of the biological dif-
ference. In order to investigate the microbial metabolic
potential of the gut microbiota in healthy controls and
RTT subjects, we applied PICRUSt (Phylogenetic Inves-
tigation of Communities by Reconstruction of Unob-
served States) [24], a computational approach used to
predict the functional composition of a metagenome
using marker gene data and a database of reference ge-
nomes. PICRUSt uses an extended ancestral-state re-
construction algorithm to predict which gene families
are present and then combines gene families to esti-
mate the composite metagenome starting from the
taxonomic composition estimated from 16S rDNA data.
Starting from a table of OTUs with associated Green-
genes identifiers, we obtained the final output from
metagenome prediction as an annotated table of pre-
dicted gene family counts for each sample, where the
encoded function of each gene family be orthologous
groups or other identifiers such as KEGG orthologues.
Spearman’s correlation tests for each correlation were
computed using the psych R package [70]. All statistical
analyses were performed using R [71].
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